WO2013101771A3 - Compositions and method for treating autoimmune diseases - Google Patents

Compositions and method for treating autoimmune diseases Download PDF

Info

Publication number
WO2013101771A3
WO2013101771A3 PCT/US2012/071456 US2012071456W WO2013101771A3 WO 2013101771 A3 WO2013101771 A3 WO 2013101771A3 US 2012071456 W US2012071456 W US 2012071456W WO 2013101771 A3 WO2013101771 A3 WO 2013101771A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
autoimmune diseases
treating autoimmune
interferon
lupus
Prior art date
Application number
PCT/US2012/071456
Other languages
French (fr)
Other versions
WO2013101771A2 (en
Inventor
Richard Boismenu
Paul BRUNETTA
Jorn DRAPPA
William D. Kennedy
Romeo MACIUCA
Jacqueline MCBRIDE
Alyssa M. Morimoto
Meina TANG
Michael J. Townsend
Xiaohui Wei
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/035313 external-priority patent/WO2012149228A1/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO2013101771A2 publication Critical patent/WO2013101771A2/en
Publication of WO2013101771A3 publication Critical patent/WO2013101771A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The invention provides methods and compositions for treating various autoimmune diseases (e.g., lupus) with an interferon inhibitor (e.g., anti-Type I interferon antibody).
PCT/US2012/071456 2011-12-30 2012-12-21 Compositions and method for treating autoimmune diseases WO2013101771A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161582179P 2011-12-30 2011-12-30
US61/582,179 2011-12-30
USPCT/US2012/035313 2012-04-26
PCT/US2012/035313 WO2012149228A1 (en) 2011-04-26 2012-04-26 Compositions and method for treating autoimmune diseases
US201261720357P 2012-10-30 2012-10-30
US61/720,357 2012-10-30

Publications (2)

Publication Number Publication Date
WO2013101771A2 WO2013101771A2 (en) 2013-07-04
WO2013101771A3 true WO2013101771A3 (en) 2013-10-10

Family

ID=48698793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/071456 WO2013101771A2 (en) 2011-12-30 2012-12-21 Compositions and method for treating autoimmune diseases

Country Status (1)

Country Link
WO (1) WO2013101771A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086074A1 (en) * 2011-04-26 2013-11-13 Genentech Inc COMPOSITIONS AND METHOD TO TREAT AUTOIMMUNE DISEASES
TW201623963A (en) * 2014-02-20 2016-07-01 麥迪紐有限責任公司 Methods of treating hepatocellular carcinoma
CN105316404B (en) * 2015-02-27 2017-02-22 中南大学湘雅二医院 Systemic lupus erythematosus biomarker and diagnostic kit thereof
WO2016176222A1 (en) 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
MA54085A (en) * 2018-10-26 2021-09-15 Janssen Biotech Inc TYPE I INTERFERON SIGNATURES AND METHODS OF USE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127756A2 (en) * 2006-04-24 2007-11-08 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2011028933A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2012162367A1 (en) * 2011-05-25 2012-11-29 Medimmune, Llc Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4690905A (en) 1983-11-16 1987-09-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method for removal of human antibodies to native DNA from serum
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
DK0463101T3 (en) 1989-03-21 1994-03-14 Immune Response Corp Inc Vaccination and treatment of diseases caused by pathogenic reactions and specific T cell populations
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DK0479909T3 (en) 1989-06-29 1997-04-07 Medarex Inc Bispecific reagents for AIDS treatment
NZ234586A (en) 1989-07-19 1993-02-25 Arthur Allen Vandenbark Peptide of a t-cell receptor capable of inducing protection from immune-related disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (en) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Heterogeneous conjugate antibody for treatment of HIV infection
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE175241T1 (en) 1992-04-03 1999-01-15 Genentech Inc ANTIBODIES AGAINST ALPHA V BETA 3 INTEGRIN
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
ES2091684T3 (en) 1992-11-13 1996-11-01 Idec Pharma Corp THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA.
DE69408541T2 (en) 1993-11-23 1998-08-06 Genentech Inc KINAS RECEPTOR ACTIVATION TEST
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998026086A1 (en) 1996-12-11 1998-06-18 University Of Florida Novel methods and compositions for treatment of autoimmune diseases
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1068241E (en) 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (en) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of immunofunctional molecules
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Process for producing polypeptide
WO2001062905A2 (en) 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
EP1276702A2 (en) 2000-03-31 2003-01-22 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
MXPA03001495A (en) 2000-08-18 2003-06-06 Ajinomoto Kk NEW PHENYLALANINE DERIVATIVES.
DE60124573T2 (en) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. NEW PHENYLALANINE DERIVATIVES
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
JP4731793B2 (en) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド Crystals of whole antibodies or fragments thereof, and methods for making and using the crystals
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4164871B2 (en) 2001-07-26 2008-10-15 味の素株式会社 Novel phenylpropionic acid derivatives
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP2005532253A (en) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド Glycoprotein composition
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk Novel phenylalanine derivative
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE60332093D1 (en) 2002-02-20 2010-05-27 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVE
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JPWO2003084569A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Antibody composition-containing medicine
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk Cells with modified genome
WO2003089410A1 (en) 2002-04-19 2003-10-30 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP4351674B2 (en) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド Immunoglobulin variants and their use and use
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase
EP2418220B1 (en) 2003-12-10 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
KR20090088932A (en) 2006-12-06 2009-08-20 메디뮨 엘엘씨 Methods of treating systemic lupus erythematosus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127756A2 (en) * 2006-04-24 2007-11-08 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
WO2011028933A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2012162367A1 (en) * 2011-05-25 2012-11-29 Medimmune, Llc Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
EBEN I LICHTMAN ET AL: "Emerging therapies for systemic lupus erythematosus Focus on targeting interferon-alpha", CLINICAL IMMUNOLOGY, vol. 143, no. 3, 30 March 2012 (2012-03-30), ACADEMIC PRESS, US, pages 210 - 221, XP028502591, ISSN: 1521-6616, [retrieved on 20120406], DOI: 10.1016/J.CLIM.2012.03.005 *
KALUNIAN K ET AL: "Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study", ARTHRITIS & RHEUMATISM, vol. 64, no. 10, Suppl. S, October 2012 (2012-10-01), & ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY (ACR) AND ASSOCIATION-OF-RHEUMATOL; WASHINGTON, DC, USA; NOVEMBER 09 -14, 2012, pages S1111, XP002697720, ISSN: 0004-3591 *
MCBRIDE JACQUELINE M ET AL: "Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.", ARTHRITIS AND RHEUMATISM, vol. 64, no. 11, November 2012 (2012-11-01), pages 3666 - 3676, XP002697719, ISSN: 1529-0131 *
MCBRIDE, JACQUELINE M, WALLACE, DANIEL J, YAO, ZHENLING, MORIMOTO, ALYSSA, JIANG, JENNY, MACIUCA, ROMEO, MCLEAN: "Dose-Dependent Modulation of Interferon Regulated Genes with Administration of Single and Repeat Doses of Rontalizumab in a Phase I, Placebo Controlled, Double Blind, Dose Escalation Study in SLE", ARTHRITIS & RHEUMATISM, vol. 60, no. Suppl. 10, 2009, The 2009 ACR/ARHP Annual Scientific MeetingPhiladelphia October 16-21, 2009, pages 2072, XP002697717, Retrieved from the Internet <URL:http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=761&id=81694> [retrieved on 20130527] *
MERRILL JOAN T ET AL: "Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study", ANNALS OF THE RHEUMATIC DISEASES, vol. 70, no. 11, November 2011 (2011-11-01), pages 1905 - 1913, XP009169832, ISSN: 0003-4967 *
WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 96, no. 1, 1 January 2007 (2007-01-01), AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, pages 1 - 26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727 *
YAO Y ET AL: "Neutralization of interferon-[alpha]/[beta]-inducible genes and downstream effect in a phase I trial of an anti-interferon-[alpha] monoclonal antibody in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, vol. 60, no. 6, 1 June 2009 (2009-06-01), JOHN WILEY & SONS, INC, US, pages 1785 - 1796, XP009147413, ISSN: 0004-3591, [retrieved on 20090528], DOI: 10.1002/ART.24557 *
YAO YIHONG ET AL: "Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN[alpha] antibody, in systemic lupus erythematosus.", ARTHRITIS RESEARCH & THERAPY, vol. 12 Suppl 1, S6, 2010, pages 1 - 7, XP002697718, ISSN: 1478-6362 *

Also Published As

Publication number Publication date
WO2013101771A2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
EP3253798A4 (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
MX2013009362A (en) Antibody against the csf-1r.
MX342240B (en) Anti-fgfr4 antibodies and methods of use.
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
MX2014002053A (en) Anti-mcsp antibodies.
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
PH12013502230A1 (en) Multispecific antibodies
WO2013006544A8 (en) Methods for making multimeric polypeptides
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
MX340555B (en) Antibodies against il-18r1 and uses thereof.
MX2014000531A (en) Methods and compositions for treating asthma using anti-il-13 antibodies.
EP3491017A4 (en) Methods for identifying lilrb-blocking antibodies
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
WO2013006449A3 (en) Anti-properdin antibodies and uses thereof
EP3307321A4 (en) Multispecific antibody platform and related methods
WO2014197885A3 (en) Inhibitors of complement factor h
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
EP3075871B8 (en) Soft magnetic steel and method for manufacturing same, and soft magnetic component obtained from soft magnetic steel
WO2013101771A3 (en) Compositions and method for treating autoimmune diseases
EP3484882A4 (en) Iso-citrate dehydrogenase (idh) inhibitor
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12824790

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12824790

Country of ref document: EP

Kind code of ref document: A2